https://www.selleckchem.com/pr....oducts/Idarubicin.ht
erm clinical trials. The VABS, as standardly administered, has shortcomings for addressing growth or regression in individuals with SCN2A-DEEs. Some subdomain raw scores reflected substantial floor effects. Raw scores increased so slowly over time that standardized scores declined. Alternative measures sensitive to incremental meaningful change are required if outcomes such as adaptive behavior are to be primary outcomes in short-term clinical trials. Randomized studies in drug-resistant epilepsy (DRE) typically involve addition of a
Like
Comment
Share
